Abstract Chimeric antigen receptor (CAR)-T cell therapy is a promising treatment for lymphoblastic leukemia and lymphoma. Despite initial response to CAR-T therapy, about 40% of patients relapse. Modulating metabolism (immunometabolism) being considering as novel approach improve efficacy. We have identified MCJ (DnaJC15) target enhance mitochondrial metabolism. an endogenous negative regulator...
